Clearmind Medicine Secures $10mln Financing to Pursue Strategic Opportunities

Clearmind Medicine has secured a $10 million securities purchase agreement to explore strategic opportunities. The company may issue convertible promissory notes in an aggregate principal amount of up to $10,000,000. The funds will be used for working capital, general corporate purposes, and potential acquisitions. The notes will accrue interest at an annual rate of 4%, increasing to 14% upon an event of default. Each note will be repaid in ten equal monthly installments commencing 18 months after its issuance date.